Ferring launches Ortikos

Ferring Pharmaceuticals is introducing Ortikos (budesonide), the only once-daily treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon, in patients 8 years of age and older, and maintenance of clinical remission in adults involving the ileum and/or the ascending colon for up to three months.

The product is available in 6-mg and 9-mg doses.

“Patients with Crohn’s disease are seeking not only safe and efficacious treatments that can provide incremental improvement, but also convenient options when managing this chronic condition,” said  Miguel Regueiro from the Cleveland Clinic. “The availability of Ortikos addresses the needs of patients, helping to treat and maintain clinical remission with one pill per day.”

“With the availability of Ortikos once-daily therapy, Ferring is now offering treatments for every stage of Crohn’s disease,” said Brent Ragans, president of Ferring US. “This is an important milestone for our company that speaks to our commitment to improving the lives of people living with Crohn’s disease and aligns with our efforts to advance gastroenterology treatments.”